Finally, we studied whether dasatinib is able to reverse the BCR-ABL induced CML phenotype, including organ infiltration by myeloid cells, splenomegaly, and bone marrow stem and progenitor cell expansion. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.